Results 151 to 160 of about 33,530 (249)

Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH)

Treatment patterns of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in Finland are unknown. Guidelines now recommend early escalation of treatment for PAH.
Wennerström, Christina, Oksanen, Minna, Soini, Erkki, Pentikäinen, Markku, the FINPAH study group, Leskelä, Pauliina, Asseburg, Christian, Harju, Terttu, Jääskeläinen, Pertti, Puhakka, Airi, Simonen, Piia, Wennerströlm, Christina   +11 more
core   +1 more source

Interlesion Time as a Key Metric of Procedural Proficiency in Atrial Fibrillation Ablation: From Fellow to Attending

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
Attending EPs performed ablation with shorter ILT, which likely contributed to more efficient procedures and reduced overall ablation time. ABSTRACT Introduction Pulmonary vein isolation (PVI) is a cornerstone of atrial fibrillation (AF) ablation. Unlike balloon‐based or pulsed field ablation, radiofrequency ablation requires precise catheter control ...
Hitoshi Mori, Daisuke Kawano, Masataka Narita, Kazuhisa Matsumoto, Tsukasa Naganuma, Wataru Sasaki, Naomichi Tanaka, Kazuhiko Kuinose, Kei Matsumoto, Yoshifumi Ikeda, Kazuo Matsumoto, Ritsushi Kato   +11 more
wiley   +1 more source

Chronic thromboembolic pulmonary hypertension: at the heart of the pulmonary arteries

Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe long-term consequence of acute pulmonary embolism (PE) and is frequently diagnosed at an advanced stage. It is characterized by thromboembolic pulmonary vascular lesions, persisting despite adequate anticoagulant therapy and leading to increased pulmonary artery pressures and ...
openaire   +2 more sources

Electrophysiological Substrate and Ablation Outcomes in Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Propensity‐Matched Multicenter Study

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
Multicentre retrospective propensity‐score‐matched cohort study (n = 286; 3 centres, Pakistan; 2015‐2023) comparing electrophysiological substrate and 12‐month ablation outcomes in patients with atrial fibrillation and hypertrophic cardiomyopathy (HCM‐AF, red) versus lone atrial fibrillation (Lone AF, green; 1:1 PSM on 14 covariates).
Umair Abrar, Fazal Ghaffar, Muhammad Zuhaid, Huzaifa Bin Afzaal, Palwasha Abbasi, Muhammad Hasnain Iqbal, Moʻminov Jahongir Zokirjon oʻgʻli, Sifat Ullah Safi   +7 more
wiley   +1 more source

The Efficacy of Left Atrial Appendage Occlusion During Thoracoscopic Epicardial AF Ablation for Improving Rhythm and Cardiac Function in Patients With Heart Failure

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
Thoracoscopic epicardial AF ablation in heart failure improved LV systolic function irrespective of left atrial appendage occlusion (LAAO). Concomitant surgical LAAO was associated with fewer LPV reconnections without worsening postoperative diastolic function, while atrial tachyarrhythmia recurrence was similar between groups.
Seongjin Park, Dong Seop Jeong, Jiwon Kim, Myoung Jung Kim, Juwon Kim, Seung‐Jung Park, Kyoung‐Min Park, Young Keun On, Ju Youn Kim   +8 more
wiley   +1 more source

Trends and Disparities in Mortality due to Pulmonary Embolism Among Adults With Atrial Fibrillation From 1999 to 2020: Insights From the CDC WONDER Database

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
National trends in mortality due to pulmonary embolism among adults with atrial fibrillation (1999–2020). ABSTRACT Background Pulmonary embolism (PE) remains a major cause of cardiovascular mortality, and atrial fibrillation (AF) significantly worsens its outcomes.
Eeman Ahmad, Mishal Khan, Muhammad Ans, Hoor Ul Ain, Ahmad Qaisar, Shahzaib Ahmed, Olivier Uwishema, Ibrahim Nagmeldin Hassan, Muhammad Saad, Abbas Hayat Mallick, M Chadi Alraies   +10 more
wiley   +1 more source

Chronic Thromboembolic Pulmonary Hypertension: A Narrative Review. [PDF]

Cureus
Jurth T, Marasco S.
europepmc   +1 more source

Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis.
Jarno Rutanen, Pekka Heino, Kati Sarnola, Terhi Kurko   +3 more
wiley   +1 more source

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension in an Adolescent With a Novel Frameshift Variant in PROS1. [PDF]

Pulm Circ
Fujii H, Isobe S, Taniguchi Y, Tamura Y.
europepmc   +1 more source

Sympatho‐Excitation in Pulmonary Hypertension: The Potential Role of Pulmonary Arterial Baroreceptors: An Acute Physiologic Intervention Study

Respirology, Volume 31, Issue 6, Page 621-629, June 2026.
Pulmonary arterial baroreceptors reflexively stimulate sympathetic nerve activity (SNA) in response to elevated pulmonary artery pressure and distension. In pulmonary hypertension patients, changes in muscle SNA were proportional to changes in pulmonary haemodynamics following nebulised iloprost.
Michael J. Plunkett, Ana L. C. Sayegh, Robert A. Lewis, Tanya J. McWilliams, Sasiharan Sithamparanathan, Julian F. R. Paton, James P. Fisher   +6 more
wiley   +1 more source